On February 24, 2021 TIAP hosted a LAB150 webinar entitled Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule.
Click to listen to a recording of the webinar:
https://zoom.us/rec/share/VllBSf8Jw4_O2mz70LGTuYQwTJb1MZ5ksnYaiY6YrsPRZI8Xfsx0B9yNRl-Q98gc._i9OthG2tcQC58eP. Access Passcode: VF2k!vXj
Here is the full description of the webinar content:
In the second of three webinars in the LAB150 series, we turn to the initial stages of identifying and developing a therapeutic compound. This follows our previous discussion of target identification and validation.
Now that you have a validated therapeutic target, how do you go about ...
On October 9, 2020, the Honourable Mélanie Joly, Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev Ontario contribution of $6.5 million to Toronto Innovation Acceleration Partners. Read more here: https://bit.ly/3nBEXDR
Under this Agreement TIAP has to date made the following investments in our portfolio startup companies:
Bitnobi - $15,000, April 1, 2019
Bright Angel Therapeutics - $30,000, August 2, 2019 and $70,000, December 23, 2020
Hypercare Inc. - $100,000, August 12, ...
TIAP's President & CEO, Parimal Nathwani, is appointed to the Government of Canada's COVID-19 Core Task Force to advise on funding of new and potential therapies for COVID-19:
Toronto, ON, July 15, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today that it is partnering with Dr. James Eubanks at the University Health Network (UHN) to develop a new treatment for Rett syndrome, a rare developmental disorder found almost exclusively in girls and women.
Infants with Rett syndrome develop and grow normally until the age of 8 to 12 months when symptoms begin appearing. Although the symptoms vary in type and severity, most of the girls and women with the disorder ...
Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the collaboration will be on a pre-clinical therapeutic developed by the Ontario Institute for Cancer Research (OICR) for the treatment of leukemia and other blood cancers, specifically targeting the WDR5 protein.
Under the terms of the agreement, Celgene has the option to acquire TRPH-395 from Triphase Accelerator. Celgene will pay an upfront amount of ...
MaRS Innovation looks back at the year that was: a summary of the main events of the past 12 months, including creation of LAB150, collaboration with strategic partners and significant investment events into our portfolio companies. For the full report, please follow the link: Year in Review 2017-18
VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI).
This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ...